75,000 Shares in Teva Pharmaceutical Industries Ltd. $TEVA Purchased by Nkcfo LLC

Nkcfo LLC acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 75,000 shares of the company’s stock, valued at approximately $2,341,000.

A number of other large investors also recently made changes to their positions in TEVA. Wealth Enhancement Advisory Services LLC grew its position in Teva Pharmaceutical Industries by 3.3% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 11,911 shares of the company’s stock valued at $382,000 after purchasing an additional 379 shares in the last quarter. Howard Bailey Securities LLC lifted its position in Teva Pharmaceutical Industries by 3.5% in the 3rd quarter. Howard Bailey Securities LLC now owns 14,451 shares of the company’s stock worth $292,000 after buying an additional 494 shares in the last quarter. ASR Vermogensbeheer N.V. boosted its stake in shares of Teva Pharmaceutical Industries by 1.6% during the 3rd quarter. ASR Vermogensbeheer N.V. now owns 31,915 shares of the company’s stock valued at $645,000 after buying an additional 515 shares during the period. CIBC Private Wealth Group LLC increased its stake in shares of Teva Pharmaceutical Industries by 15.5% in the third quarter. CIBC Private Wealth Group LLC now owns 4,020 shares of the company’s stock worth $81,000 after acquiring an additional 540 shares during the last quarter. Finally, Retirement Planning Co of New England Inc. increased its stake in shares of Teva Pharmaceutical Industries by 1.8% in the third quarter. Retirement Planning Co of New England Inc. now owns 33,230 shares of the company’s stock worth $671,000 after acquiring an additional 588 shares during the last quarter. Institutional investors and hedge funds own 54.05% of the company’s stock.

Key Teva Pharmaceutical Industries News

Here are the key news stories impacting Teva Pharmaceutical Industries this week:

• Positive Sentiment: Q1 earnings and revenue beat — Teva reported Q1 results above estimates with branded drugs (Austedo, Ajovy, Uzedy) driving growth and net income/earnings gains, which sparked the immediate market rally. TEVA Q1 Earnings Top Estimates
• Positive Sentiment: Multiple analyst upgrades and higher price targets — Truist, UBS, JPMorgan and Piper Sandler raised price targets (Truist to $45, UBS to $42, JPMorgan to $40, Piper to $42) and reiterated buy/overweight views, signaling expected upside and supporting the stock’s momentum. Analyst Notes (Benzinga) Truist Note (TickerReport)
• Positive Sentiment: Strategic acquisition — Teva agreed to buy Emalex Biosciences (up to ~$900M, $700M cash upfront) to add ecopipam (NDA‑ready for pediatric Tourette’s) to its neuroscience pipeline, boosting growth optionality beyond generics. Teva to Acquire Emalex Biosciences
• Positive Sentiment: Sustainability-linked bond targets met — Teva said it exceeded all targets tied to ~$7.5B of sustainability-linked bonds, which reduces ESG-related execution risk and may appeal to ESG-focused investors. 2025 Healthy Future Report
• Positive Sentiment: Signs of institutional bullishness — Large call-option activity and reported interest from private capital (e.g., Blackstone financing coverage) indicate increased investor conviction and speculative/hedging flows into the shares. Blackstone Coverage
• Neutral Sentiment: Industry positioning and market analysis — Reports list Teva among leaders in the oral solid dosage contract manufacturing market, reflecting scale and potential contract-manufacturing tailwinds over the medium term. Oral Solid Dosage Market Analysis
• Neutral Sentiment: Product-level wins — Uzedy U.S. net sales rose to $63M in Q1 (strong growth rate but still early in scale), supporting the narrative of branded recovery even as the company rebalances its portfolio. UZEDY Sales Report
• Negative Sentiment: Generics pressure and localized revenue declines — Management flagged weaker generics performance and a slight revenue decline in local currency (and continued pressure from lenalidomide generic dynamics), which remains a structural risk for margins and growth if branded momentum slows. Q1 Results & Commentary

Insiders Place Their Bets

In other Teva Pharmaceutical Industries news, EVP Richard Daniell sold 17,295 shares of the business’s stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $31.67, for a total transaction of $547,732.65. Following the completion of the transaction, the executive vice president owned 85,755 shares of the company’s stock, valued at $2,715,860.85. The trade was a 16.78% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Richard D. Francis sold 442,935 shares of the company’s stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $32.36, for a total transaction of $14,333,376.60. Following the sale, the chief executive officer owned 642,099 shares of the company’s stock, valued at $20,778,323.64. This trade represents a 40.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 920,901 shares of company stock worth $30,056,789 in the last ninety days. 0.54% of the stock is owned by insiders.

Analyst Ratings Changes

A number of analysts recently issued reports on TEVA shares. Scotiabank lifted their price objective on Teva Pharmaceutical Industries from $35.00 to $40.00 and gave the company a “sector outperform” rating in a research report on Thursday, January 29th. Piper Sandler reiterated an “overweight” rating and set a $42.00 price target (up from $41.00) on shares of Teva Pharmaceutical Industries in a report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a report on Monday, April 20th. Jefferies Financial Group lifted their target price on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Finally, UBS Group increased their price target on shares of Teva Pharmaceutical Industries from $36.00 to $42.00 and gave the stock a “buy” rating in a research note on Thursday. Nine investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $41.56.

Teva Pharmaceutical Industries Stock Down 1.0%

TEVA opened at $35.03 on Friday. The business has a 50 day moving average price of $31.15 and a 200 day moving average price of $29.33. Teva Pharmaceutical Industries Ltd. has a twelve month low of $14.99 and a twelve month high of $37.35. The company has a debt-to-equity ratio of 1.89, a quick ratio of 0.80 and a current ratio of 1.04. The firm has a market cap of $40.28 billion, a P/E ratio of 26.34, a price-to-earnings-growth ratio of 3.12 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings results on Tuesday, March 31st. The company reported $0.53 EPS for the quarter. Teva Pharmaceutical Industries had a return on equity of 44.86% and a net margin of 9.01%.The company had revenue of $3.98 billion for the quarter. Research analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.6 EPS for the current year.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.